Generics of the Major Anticancer Drug TS-1 Launched by Just 2 Companies Due to Development Hurdles

The first generic versions of the anticancer drug TS-1 (tegafur + gimeracil + oteracil) have reached the market. TS-1 is a major product with annual sales approaching 40 billion yen, but only Sawai Pharmaceutical and Nippon Kayaku have launched generics...read more